Meeting Banner
Abstract #0508

Diffusion Weighted Imaging Detects Significant Cohort Responses After Seven Days of Treatment with Cediranib in a Phase I Clinical Trial Setting

Matthew R. Orton1, Christina Messiou2, David John Collins1, Veronica A. Morgan2, Dionysis Papadatospastos3, Andre Brunetto3, Jooern Ang3, Helen Mann4, Jean Tessier4, Helen Young4, Stan Kaye3, Johann S. de Bono3, Martin O. Leach1, Nandita M. De Souza1

1CR-UK and EPSRC Cancer Imaging Centre, Institute of Cancer Research, Sutton, Surrey, United Kingdom; 2Radiology Department, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; 3Department of Medicine, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; 4AstraZeneca, Macclesfield, Cheshire, United Kingdom

Although DWI measures have previously been reported demonstrating changes with anti-angiogenic agents at 28 days, the response at 7 days has not been widely reported as it is assumed that DWI is insensitive to perfusion changes with an antiangiogenic agent in such a short time-frame. The purpose of this study was to assess changes in DWI derived measures at both 7 and 28 days for a cohort of patients treated with Cediranib. Significant cohort changes are seen at 7 days and these can be detected using a number of diffusion attenuation models, in particular with the stretched-exponential model.